EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.

Employees

Sector

Drug Retailers

Calendar

11-05 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
26-09-02	SEK 25.40	-1.55%	10,085
26-09-01	SEK 25.80	-4.62%	21,420
26-08-31	SEK 27.05	+4.04%	32,403
26-08-28	SEK 26.00	-4.76%	84,560
26-08-27	SEK 27.30	-3.36%	26,248

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 05:49:32 2026-09-02 EDT			5-day change	1st Jan Change
25.40 ^SEK	-1.55%		-10.09%	-56.06%

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW

Market Cap	762M 79.42M 68.51M 64.44M 58.71M 110M 7.54B 111M 297M 3.83B 298M 292M 12.71B	P/E 2027 *	-	P/E 2028 *	10.8x
Enterprise Value	1.18B 123M 106M 99.72M 90.85M 171M 11.66B 172M 459M 5.93B 461M 451M 19.67B	EV / Sales 2027 *	2.42x	EV / Sales 2028 *	1.95x
Free-Float	42.3%	Yield 2027 *	-	Yield 2028 *	-

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW
08-14	DNB Carnegie raises its justified value for EQL Pharma	FW
08-12	EQL Pharma Enters UTI Treatment License Deal in Hungary	MT
08-12	EQL Pharma: Analysguiden cuts fair value estimate to 38 kronor	FW
08-12	EQL Pharma licenses Memprex to partner in Hungary	FW
08-12	EQL Pharma AB Licenses Memprex for Sale in Hungary	CI
08-07	EQL Pharma AB, Q1 2027 Earnings Call, Aug 07, 2026
08-07	EQL Pharma AB Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO (update)	FW
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO	FW
08-07	Eql Pharma AB Provides Earnings Guidance for the Year 2026/27	CI
07-28	DNB Carnegie cuts justified value for EQL Pharma	FW

08-14	DNB Carnegie raises its justified value for EQL Pharma	FW
08-12	EQL Pharma: Analysguiden cuts fair value estimate to 38 kronor	FW
07-28	DNB Carnegie cuts justified value for EQL Pharma	FW
05-13	Aktiespararna lowers fair value for EQL Pharma to SEK 46 (77) - commissioned research	FW
05-11	DNB Carnegie lowers fair value for EQL Pharma	FW

EQL Pharma AB Stock

Stocks

EQL

SE0005497732

Drug Retailers

Valuation : EQL Pharma AB

Chart: EQL Pharma AB

Latest news : EQL Pharma AB

Last Transcript : EQL Pharma AB

Analysts' recommendations : EQL Pharma AB

Press Releases : EQL Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors : EQL Pharma AB

Latest insider transactions

Other Drug Retailers

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-20	Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026	AQ
08-14	EQL Pharma: Improvement emerging, confirmation needed – Q1 review	AQ
08-12	Memprex© (methenamine hippurate) license signed with partner for Hungary	AQ
08-07	EQL Pharma: Soft start as expected, guidance intact	AQ
08-07	Interim Report April - June 2026	AQ

1 day	-1.55%
1 week	-10.09%
Current month	-6.10%
1 month	+19.53%
3 months	+8.78%
6 months	-55.28%
Current year	-56.06%

1 week	24.55	28.2
1 month	17.38	28.3
Current year	17.38	67.5
1 year	17.38	88.1
3 years	17.38	98.6
5 years	17.38	98.6
10 years	6.35	98.6

Manager	Title	Age	Since
Axel Schörling CEO	Chief Executive Officer	40	2022-08-16
Allan Sylvest Aasberg DFI	Director of Finance/CFO	51	2026-03-31
Martin Kristofferson COO	Chief Operating Officer	48	2022-08-16

Director	Title	Age	Since
Lars Christer Fedrik Fåhraeus CHM	Chairman	61	2022-08-16
Anders Månsson CHM	Chairman	59	-
Ingrid Linda Marie Neckmar BRD	Director/Board Member	53	2019-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/14/26	Allan Sylvest Aasberg	Buy	Chief Financial Officer	20,000	0.0677%
3/27/26	Axel Schörling	Sell	Chief Executive Officer	24,066	0.0815%
12/30/25	Magnus Erreth	Buy	Executive/Senior Manager	1,000	0.0034%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EQL PHARMA AB	-1.55%	-10.09%	-69.10%	-8.96%	79.42M
JD HEALTH INTERNATIONAL INC.	+1.48%	-0.80%	-41.32%	-16.29%	14.83B
MATSUKIYOCOCOKARA & CO.	-1.40%	-0.45%	-16.54%	-11.10%	6.4B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-0.49%	-4.38%	-50.00%	-36.09%	6.33B
YIFENG PHARMACY CHAIN CO., LTD.	+0.26%	-3.61%	-2.42%	-21.35%	4.14B
NAHDI MEDICAL COMPANY	-0.16%	-1.75%	-20.79%	-37.85%	3.21B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-0.22%	0.00%	+8.74%	-30.19%	3.12B
CLICKS GROUP LIMITED	+4.03%	+3.50%	-44.25%	-23.42%	3B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	-3.26%	-2.37%	-18.53%	-9.57%	2.51B
GUARDIAN PHARMACY SERVICES, INC.	+4.80%	+4.21%	+47.12%	-	2.46B
Average	+0.35%	-1.15%	-20.71%	-21.65%	4.61B
Weighted average by Cap.	+0.55%	-1.83%	-25.03%	-21.55%

	2027 *	2028 *
Net sales	486M 50.72M 43.75M 41.15M 37.49M 70.5M 4.81B 70.88M 189M 2.45B 190M 186M 8.12B	612M 63.85M 55.08M 51.81M 47.2M 88.76M 6.06B 89.24M 238M 3.08B 240M 235M 10.22B
Net income	-	71M 7.4M 6.38M 6.01M 5.47M 10.29M 702M 10.34M 27.63M 357M 27.79M 27.19M 1.18B
Net Debt	417M 43.47M 37.5M 35.27M 32.13M 60.43M 4.13B 60.76M 162M 2.1B 163M 160M 6.96B	430M 44.83M 38.67M 36.37M 33.14M 62.31M 4.25B 62.65M 167M 2.16B 168M 165M 7.18B